|
|
|
Volumn 5, Issue 1, 2007, Pages 13-14
|
|
E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
FARNESYL TRANS TRANSFERASE;
QUINOLONE DERIVATIVE;
TIPIFARNIB;
ACUTE NONLYMPHOCYTIC LEUKEMIA;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ANTAGONISM;
HUMAN;
MIDDLE AGED;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SALVAGE THERAPY;
TUMOR RECURRENCE;
AGED;
ANTINEOPLASTIC AGENTS;
FARNESYLTRANSTRANSFERASE;
HUMANS;
LEUKEMIA, NONLYMPHOCYTIC, ACUTE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
QUINOLONES;
SALVAGE THERAPY;
|
|
EID: 33947496690
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|